Literature summary for 1.14.14.55 extracted from

Mirghani, R.A.; Sayi, J.; Aklillu, E.; Allqvist, A.; Jande, M.; Wennerholm, A.; Eriksen, J.; Herben, V.M.; Jones, B.C.; Gustafsson, L.L.; Bertilsson, L.
CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population (2006), Pharmacogenet. Genomics, 16, 637-645.

Search for more literature for 1.14.14.55

Cloned(Commentary)

Cloned (Comment)	Organism
genes CYP3A5 and CYP3A4, DNA sequence determination, genotyping of two different human populations revealing the CYP3A5 and the CYP3A4 genotypes	Homo sapiens

Protein Variants

Protein Variants	Comment	Organism
A6986AG	single nucleotide polymorphism responsible for different CYP3A genotypes, CYP3A5 allele and genotype frequency in the populations, overview	Homo sapiens
additional information	the CYP3A5 genotype has significant effect on quinine 3-hydroxylation in black Tanzanians, who have lower total CYP3A activity compared to a population of Swedish caucasians, overview	Homo sapiens

Natural Substrates/ Products (Substrates)

Natural Substrates	Organism	Comment (Nat. Sub.)	Natural Products	Comment (Nat. Pro.)	Rev.	Reac.
quinine + NADPH + O2	Homo sapiens	quinine is used for treatment of severe forms of Plasmodium falciparum malaria, phenotyping of two different populations, overview	3-hydroxyquinine + NADP+ + H2O	-	?

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
quinine + NADPH + O2	-	Homo sapiens	3-hydroxyquinine + NADP+ + H2O	-	?
quinine + NADPH + O2	quinine is used for treatment of severe forms of Plasmodium falciparum malaria, phenotyping of two different populations, overview	Homo sapiens	3-hydroxyquinine + NADP+ + H2O	-	?

Synonyms

Synonyms	Comment	Organism
CYP3A	-	Homo sapiens

Cofactor

Cofactor	Comment	Organism	Structure
NADPH	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)